These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11802256)

  • 1. Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers.
    Tan KH; Hyman-Tylor P; Mulheran M; Knox A; Smyth A
    Pediatr Pulmonol; 2002 Feb; 33(2):165. PubMed ID: 11802256
    [No Abstract]   [Full Text] [Related]  

  • 2. Tobramycin dosing in cystic fibrosis.
    Smyth A; Touw D; Tan KH; Bertenshaw C; Stableforth D
    Lancet; 2005 May 21-27; 365(9473):1767-8. PubMed ID: 15910946
    [No Abstract]   [Full Text] [Related]  

  • 3. Tobramycin inhalation solution (Bethkis) for cystic fibrosis.
    Med Lett Drugs Ther; 2014 Jun; 56(1445):51-2. PubMed ID: 24956309
    [No Abstract]   [Full Text] [Related]  

  • 4. Minimizing the toxicity of aminoglycosides in cystic fibrosis.
    Smyth AR
    J R Soc Med; 2010 Jul; 103 Suppl 1(Suppl 1):S3-5. PubMed ID: 20573667
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
    Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
    Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
    Vandenbussche HL; Klepser ME
    Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
    [No Abstract]   [Full Text] [Related]  

  • 7. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
    Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
    J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
    [No Abstract]   [Full Text] [Related]  

  • 8. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
    Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
    [No Abstract]   [Full Text] [Related]  

  • 9. Unwarranted use of intravenous aminoglycosides at UK paediatric cystic fibrosis centres.
    Ditchfield N; Carroll WD; Gilchrist FJ
    J Cyst Fibros; 2019 Nov; 18(6):e58-e59. PubMed ID: 31522925
    [No Abstract]   [Full Text] [Related]  

  • 10. [Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection].
    Mordasini C; Aebischer CC; Schoch OD
    Schweiz Med Wochenschr; 1997 May; 127(21):905-10. PubMed ID: 9289818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis.
    Akbar A; Rees JH; Nyamugunduru G; English MW; Spencer DA; Weller PH
    Acta Paediatr; 1999 Jul; 88(7):783-5. PubMed ID: 10447142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis.
    Nikolaizik WH; Jenni-Galović V; Schöni MH
    Eur J Pediatr; 1996 Jul; 155(7):608-11. PubMed ID: 8831087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosis.
    Nolan K; Knight H; Clark P
    Lancet Respir Med; 2013 Apr; 1(2):102-3. PubMed ID: 24429083
    [No Abstract]   [Full Text] [Related]  

  • 14. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
    Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
    Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.
    Hamed K; Debonnett L
    Ther Adv Respir Dis; 2017 May; 11(5):193-209. PubMed ID: 28470103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease.
    Paporisz U; Posselt HG; Wönne R; Ristow W; Röser D; Knothe H; Bender SW
    Monogr Paediatr; 1979; 10():31-3. PubMed ID: 460275
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
    Hodson ME; Gallagher CG; Govan JR
    Eur Respir J; 2002 Sep; 20(3):658-64. PubMed ID: 12358344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
    Pierart F
    Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pseudomonas infections in cystic fibrosis using tobramycin.
    McCrae WM
    Scott Med J; 1976 Apr; 21(2):68-9. PubMed ID: 940997
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
    Hennig S; McKay K; Vidmar S; O'Brien K; Stacey S; Cheney J; Wainwright CE
    J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.